Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Moderna Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Moderna şirketinin kazançları yıllık ortalama -2.3% oranında azalırken, Biotechs sektörünün kazançları yıllık 13.4% oranında artan oldu. Gelirler yıllık ortalama 31.7% oranında artan oldu.

Anahtar bilgiler

-2.3%

Kazanç büyüme oranı

-2.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi	14.8%
Gelir büyüme oranı	31.7%
Özkaynak getirisi	-50.1%
Net Marj	-116.2%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Moderna nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

WBAG:MRNA Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	5,050	-5,867	1,454
31 Mar 24	5,153	-5,968	1,518
31 Dec 23	6,848	-4,714	1,549
30 Sep 23	9,121	-3,466	1,454
30 Jun 23	10,654	1,207	1,290
31 Mar 23	15,059	4,784	1,169
31 Dec 22	19,263	8,362	1,132
30 Sep 22	21,390	11,765	958
30 Jun 22	22,995	14,055	848
31 Mar 22	22,600	14,638	758
31 Dec 21	18,471	12,202	567
30 Sep 21	11,831	7,061	445
30 Jun 21	7,019	3,495	325
31 Mar 21	2,732	598	241
31 Dec 20	803	-747	188
30 Sep 20	246	-597	135
30 Jun 20	106	-488	115
31 Mar 20	52	-505	106
31 Dec 19	60	-514	110
30 Sep 19	82	-535	122
30 Jun 19	106	-499	112
31 Mar 19	122	-459	105
31 Dec 18	135	-402	94
30 Sep 18	192	-299	72
30 Jun 18	192	-280	70
31 Mar 18	199	-266	65
31 Dec 17	206	-270	65
31 Dec 16	108	-230	57

Kaliteli Kazançlar: MRNA şu anda kârlı değil.

Büyüyen Kar Marjı: MRNA şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MRNA kârlı değildir ve zararlar son 5 yılda yılda 2.3% oranında artmıştır.

Büyüme Hızlandırma: MRNA 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: MRNA kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -18.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: MRNA hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -50.09% ) sahiptir.

Moderna Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: US$9.53 loss per share (vs US$2.67 profit in 3Q 2022)

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Investor sentiment deteriorates as stock falls 16%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$3.62 loss per share (vs US$5.55 profit in 2Q 2022)

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin